复方紫紧对烫伤小鼠肠道免疫功能的影响

目的：研究ＺＧ对烧伤后肠道免疫功能的调节。方法：４０％体表面积（ＴＢＳＡ）Ⅲ度烫伤大鼠灌喂复方紫归（ＺＧ）３ｇ／ｋｇ，２／ｄ，共３ｄ（ＺＧ组），灌喂０。９％生理盐水８ｍｌ／ｋｇ，２／ｄ，共３ｄ（对照组）。结果：ＺＧ组肠道内容积物ＩｇＧ含量明显高于对照组（Ｐ〈０．０５）；ＺＧ组肠固有层ＣＤ３＾＋Ｔ淋巴细胞活性明显增强（Ｐ〈０．０５）；ＺＧ组血浆ＬＰＳ、ＭＤＡ明显低于对照组（Ｐ〈０．０５）。结论：复方     

复方紫归对烫伤大鼠肠道免疫功能的影响

目的：研究ＺＧ对烧伤后肠道免疫功能的调节。方法：４０％体表面积（ＴＢＳＡ）Ⅲ度烫伤大鼠灌喂复方紫归（ＺＧ）３ｇ／ｋｇ，２／ｄ，共３ｄ（ＺＧ组），灌喂０．９％生理盐水８ｍｌ／ｋｇ，２／ｄ，共３ｄ（对照组）。结果：ＺＧ组肠道内容物ＩｇＡ含量明显高于对照组（Ｐ＜０．０５）；ＺＧ组肠固有层ＣＤ３＋Ｔ淋巴细胞活性明显增强（Ｐ＜０．０５）；ＺＧ组血浆ＬＰＳ、ＭＤＡ明显低于对照组（Ｐ＜０．０５）。结论：复方紫归对烫伤大鼠肠道免疫功能有一定的保护作用，可减轻肠道缺血再灌注损伤和肠源性内毒素血症。     

阿司匹林对二甲基肼诱发大鼠结肠癌的影响

Ｗｉｓｔａｒ大鼠７５只分５组，分别灌饲阿司匹林６０，０．５，３０及６０ｍｇ（ｋｇ．ｄ），除第１组外，周末每组大鼠注二甲基肼３０ｍｇ／ｋｇ，至１８周处死动物，取结肠沿长轴剖开，洗净，纪录病变部位，形态及直径。结果显示随阿司匹林剂量增加，结肠肿瘤数目减少；≥５ｍｍ肿瘤百分比降低（Ｐ〈０．０１）。表明阿司匹林可减少结肠癌形成。     

蚯蚓纤溶酶对犬纤溶酶活性和血小板聚集功能的影响

目的研究口服蚯蚓纤溶酶（ＥＦＥ）对纤溶系统和血小板聚集功能的影响。方法正常雄性Ｂｅａｇｌｅ犬，体重６．５～９ｋｇ，经口给蚯蚓纤溶酶，经前肢静脉取血。以Ｓ－２２５１为发色底物，测定血浆纤溶酶活性；５０μｍｏｌ／ＬＡＤＰ为诱导剂测定血小板聚集率。结果（１）单剂量ＥＦＥ４０、８０ｍｇ／ｋｇ后血浆纤溶酶活性升高（Ｐ＜０．０５），８０ｍｇ／ｋｇ组高于４０ｍｇ／ｋｇ组（Ｐ＜０．０５）。连续给药１０ｄ，４０、８０ｍｇ／ｋｇ组均有多个时间点纤溶酶活性升高（Ｐ＜０．０５），但两组间无差异。（２）单剂量ＥＦＥ４０ｍｇ／ｋｇ，或经口给阿司匹林８ｍｇ／ｋｇ后３ｈ，血小板聚集均被抑制（Ｐ＜０．０５）；而在单剂量ＥＦＥ８０ｍｇ／ｋｇ或经口给淀粉后３ｈ，血小板聚集功能均无变化。结论ＥＦＥ经口给药可提高血浆纤溶酶活性，并在一定剂量下可抑制血小板的聚集。     

山茱萸对延长大鼠异位心脏移植存活的作用

目的：观察山茱萸水煎剂对大鼠异位移植心脏排异的抑制作用。方法：异位移植心脏的大鼠分成４组：Ⅰ组为对照，喂生理盐水；Ⅱ组喂山茱萸水煎剂２０ｇ／（ｋｇ·ｄ）；Ⅲ组喂环孢菌素Ａ（ＣｓＡ）５ｍｇ／（ｋｇ·ｄ）；Ⅳ组喂ＣｓＡ５ｍｇ／（ｋｇ·ｄ）和山茱萸水煎剂２０ｇ／（ｋｇ·ｄ）。结果：Ⅰ组（ｎ＝１３）移植心脏存活１３７±３７ｄ；Ⅱ组（ｎ＝１０）存活２８５±６２ｄ，另有２只移植心脏存活＞１ａ；Ⅲ组（ｎ＝７）存活４０１±６９ｄ，另有１只存活５个月；Ⅳ组（ｎ＝７）存活４９７±８０ｄ，另有１只存活５个月，１只存活＞８个月。Ⅱ组与Ⅰ组间、Ⅳ组与Ⅱ组间均有非常显著差异（Ｐ＜００１）；Ⅳ组与Ⅲ组间有显著差异（Ｐ＜００５）。结论：山茱萸水煎剂能抑制排斥，显著延长大鼠异位移植心脏存活；山茱萸与ＣｓＡ联合应用比单用ＣｓＡ或山茱萸效果更好，二者有相加作用     

利多卡因预防异丙酚静注痛的最佳剂量探讨

为探讨利多卡因预防异丙酚静注痛的最佳剂量，１２０例ＡＳＡＩ～Ⅱ级择期手术患者，随机分为例数相等的四组，Ｉ组：异丙酚，Ⅱ组：异丙酚＋利多卡因０．１ｍｇ／ｋｇ；Ⅲ组：异丙酚＋利多卡因０．３ｍｇ／ｋｇ，Ⅳ组：异丙酚＋利多卡因０．５ｍｇ／ｋｇ。异丙酚的用量均为２．５ｍｇ／ｋｇ，结果：Ⅱ，Ⅲ，Ⅳ组异丙酚静注痛的发生率明显低于Ｉ组（Ｐ〈０．０１～０．０５），而Ⅱ，Ⅲ，Ⅳ组间异丙酚静注痛的发生率无显著性差异（Ｐ     

输精管结扎后家兔血清及精浆的前列腺酸性磷酸酶活力变化

成年日本大耳白雄兔４２只，随机分为输精管结扎２５月组（ＶＧ２５）１４只和假手术２５月组（ＳＯＧ２５）１１只；输精管结扎６月组（ＶＧ６）９只和假手术６月组（ＳＯＧ６）８只，均于体重２．５～３．０ｋｇ（５月龄）行时输精管结扎或假手术，在相同条件下检测前列腺酸性磷酸酶（ＰＡＰ）的活力结果表明；（１）血清ＰＡＰ活力，有随增龄增高的趋势，输精管结扎对该酶活性无影响（Ｐ〉０．０５）。（２）精子ＰＡＰ活力，ＶＧ     

牛磺酸对缺血大鼠心肌细胞膜ATP酶活性的影响

研究缺血大鼠心肌细胞膜ＡＴＰ酶活性改变及牛磺酸的影响。给Ｗｉｓｔａｒ大鼠皮下注射异丙肾上腺素（ＩＳＰ５ｍｇ／ｋｇ）制造心肌缺血损伤模型，另一组在注射ＩＳＰ前３０ｍｉｎ腹腔注射牛黄酸２００ｍｇ／ｋｇ及对照组注射等量生理盐水。观测心肌细胞膜Ｋ＋·Ｎａ＋－ＡＴＰ酶，Ｃａ２＋－ＡＴＰ酶活性，丙二醛（ＭＤＡ）含量及心肌钙含量。结果显示，缺血组Ｃａ２＋－ＡＴＰ酶和Ｋ＋，Ｎａ＋－ＡＴＰ酶活性分别降低４８．２３％和４５．８５％（Ｐ＜０．０１），ＭＤＡ含量升高８０％（Ｐ＜０．０１），牛磺酸保护组未见显著性变化。并发现Ｋ＋、Ｎａ＋－ＡＴＰ酶和Ｃａ２＋－ＡＴＰ酶活性与ＭＤＡ含量之间有显著负相关（Ｐ＜０．０５）。结果提示，牛磺酸可通过抑制心肌ＭＤＡ生成，实现它对心肌细胞膜Ｃａ２＋－ＡＴＰ酶和Ｋ＋·Ｎａ＋－ＡＴＰ酶活性的保护作用。     

分次小剂量鱼精蛋白拮抗肝素的临床运用

目的：观察使用分次小剂量鱼精蛋白拮抗体外循环后体内残存肝素的可行性。方法：选择ＡＳＡⅡ～Ⅲ级瓣膜替换手术患者４０例，随机分为鱼精蛋白大剂量组（Ａ，ｎ＝２０）和小剂量组（Ｂ，ｎ＝２０）。大剂量组鱼精蛋白总量为４．５ｍｇ／ｋｇ，分为首剂（４ｍｇ／ｋｇ）和追加量（０．５ｍｇ／ｋｇ），间隔３０ｍｉｎ，均以中心静脉推注；Ｂ组鱼精蛋白总量为２．５ｍｇ／ｋｇ，分为２ｍｇ／ｋｇ和０．５ｍｇ／ｋｇ两次给入，方法同Ａ组。观察全血激活凝固时间（ＡＣＴ）和术后２４ｈ渗血量。结果：（１）给药后１５ｍｉｎＢ组ＡＣＴ短于Ａ组（Ｐ＜０．０１）；（２）给药后３０ｍｉｎ两组ＡＣＴ均有不同程度延长，但差异无显著性（Ｐ＞０．０５）；给药后４５ｍｉｎ（追加量后１５ｍｉｎ）Ｂ组ＡＣＴ明显短于Ａ组（Ｐ＜０．０１）；（３）Ｂ组术后２４ｈ渗血量明显少于Ａ组（Ｐ＜０．０１）。结论：使用小剂量分次鱼精蛋白法拮抗体外循环后体内残存肝素，效果确切，具有减少鱼精蛋白用量和术后出血量的作用。     

1,6—二磷酸果糖抗失血性休克实验研究

本实验观察了ＦＤＰ抗失血性休克作用。３组失血性休克大鼠分别接受５％ＦＤＰ溶液（Ａ组）、５％葡萄糖溶液（Ｂ组）和生理盐水（Ｃ组）静注。给药６０ｍｉｎ后，Ａ组ＭＡＰ为１０．４±２．１ｋＰａ，与Ｂ、Ｃ组７．９±２．４和７．７±２．６ｋＰａ间均有差异（Ｐ＜０．０１）；Ａ组动物存活率７５％，而Ｂ、Ｃ组分别为２５％和１５％（Ｐ＜０．０１）；Ａ组动脉血ｐＨ和ＰａＯ２分别为７．２４±０．１４和１３．４６±１．２２ｋＰａ，与Ｂ、Ｃ组７．１４±０．１４和１０．２９±３．８４ｋＰａ与７．０２±０．１０和７．２５±２．１２ｋＰａ间有显著差异（Ｐ＜０．０１）；Ａ组回输血液再灌流后血浆ＳＯＤ和ＭＤＡ分别为１２００±１２６Ｕｍｌ－１和０．４７±０．２５ｎｍｏｌｍｌ－１，同Ｂ、Ｃ组１０８１±１１９Ｕｍｌ－１和０．９１±０．２９ｎｍｏｌ－１与８３５±９Ｕｍｌ－１和１．１３±０．１６ｎｍｏｌ－１间均有显著差异（Ｐ＜０．０１）。结果表明ＦＤＰ保护组织损伤而产生抗休克作用。     

脑供血动脉支架置入术前不同抗血小板治疗方案的初步疗效评价

目的 采用血栓弹力图（TEG）检测拟行颅内外动脉支架置入术前患者双联抗血小板治疗后血小板抑制情况,寻找术前最佳给药时间、给药剂量,以指导临床。方法 据既往是否有单纯阿司匹林服用史及术前阿司匹林不同给药剂量,将我院93例患者,分为4组,分别为:无服药史低剂量组(阿司匹林100 mg+氯吡格雷75 mg)、无服药史高剂量组(阿司匹林300 mg+氯吡格雷75 mg)、有服药史低剂量组、有服药史高剂量组。TEG检测服药后1 d和服药后3 d花生四烯酸(AA)通路血小板抑制率和二磷酸腺苷(ADP)通路血小板抑制率。结果 不同时间点分析:既往无服药史低剂量组,服药后3 d血小板抑制率\[AA: (89.09±17.42)%, ADP: (57.02±23.97)%\]高于服药后1 d\[AA:(82.24±22.25)%,ADP: (49.62±25.44)%\],差异有统计学意义(P<0.05);既往无服药史高剂量组,服药后3 d血小板抑制率\[AA: (95.06±8.05)%,ADP: (47.76±24.95)%\]高于服药后1 d\[AA:(88.88±14.66)%,ADP: (36.17±22.71)%\],差异有统计学意义(P<0.05)。不同剂量分析:相同服药时间下,无服药史低剂量组与高剂量组、有服药史低剂量组与高剂量组,AA通路抑制率差异均无统计学意义。结论 对既往未服用过阿司匹林的脑血管病患者,支架置入术前抗血小板治疗3 d比治疗1 d可达到更好的血小板抑制效果,而低剂量与高剂量间血小板抑制效果相当。     

Association of the Platelet Membrane Glycoprotein Ⅰ a C807T Gene Polymorphism with Aspirin Resistance

To explore the correlation between the C807T polymorphism of platelet membrane gly- coprotein Ⅰa (GPⅠa) gene and aspirin resistance in Chinese people, 200 patients with high-risk of atherosclerosis took aspirin (100 mg/d) for 7 days. Platelet aggregation function was detected using adenosine diphosphate (ADP) and arachidonic acid (AA) before and after the administration of aspi- rin. Then the subjects were divided into three groups according to the results of platelet aggregation function: an aspirin resistant (AR) group, an aspirin semi-responder (ASR) group and an aspi- rin-sensitive (AS) group. Platelet GPⅠa gene 807CT polymorphism was examined by means of po- lymerase chain reaction-sequence specific primers (PCR-SSP). The results showed that T allelic fre- quency in AR group and ASR group were higher that of AS group (P<0.005), and the prevalence of genotypes (TT TC) of these two groups was significantly higher than that in AS group (P<0.05). Platelet GPⅠa T allele was significantly associated with aspirin resistance as revealed by multiple logistic regression (OR=3.76, 95% CI: 2.87–9.58). The results suggest that inherited platelet GPⅠa variations may have an important impact on aspirin resistance and the presence of GPⅠa T allele may be a marker of genetic susceptibility to aspirin resistance.     

Association of the platelet membrane glycoprotein I a C807T gene polymorphism with aspirin resistance

Summary To explore the correlation between the C807T polymorphism of platelet membrane glycoprotein I a (GP I a) gene and aspirin resistance in Chinese people, 200 patients with high-risk of atherosclerosis took aspirin (100 mg/d) for 7 days. Platelet aggregation function was detected using adenosine diphosphate (ADP) and arachidonic acid (AA) before and after the administration of aspirin. Then the subjects were divided into three groups according to the results of platelet aggregation function: an aspirin resistant (AR) group, an aspirin semi-responder (ASR) group and an aspirin-sensitive (AS) group. Platelet GP I a gene 807CT polymorphism was examined by means of polymerase chain reaction-sequence specific primers (PCR-SSP). The results showed that T allelic frequency in AR group and ASR group were higher that of AS group (P<0.005), and the prevalence of genotypes (TT+TC) of these two groups was significantly higher than that in AS group (P<0.05). Platelet GP I a T allele was significantly associated with aspirin resistance as revealed by multiple logistic regression (OR=3.76, 95% CI: 2.87–9.58). The results suggest that inherited platelet GP I a variations may have an important impact on aspirin resistance and the presence of GP I a T allele may be a marker of genetic susceptibility to aspirin resistance.     

阿加曲班或低分子肝素联合阿司匹林对于早期进展性缺血性卒中的疗效和安全性

目的：观察和比较阿加曲班或低分子肝素（LMWH）联合阿司匹林对于早期进展性缺血性卒中（PIS的疗效和安全性。方法：将95例符合标准的PIS患者随机分为两组,阿加曲班联合阿司匹林组48例（AA组）,LMWH联合阿司匹林组47例（LA组）。比较两组治疗前后的美国国立卫生研究院卒中量表（NIHSS）、日常生活能力评定量表（Barthel指数）、改良Rankin量表（mRS）。同时监测血红蛋白（Hb）浓度、血小板（PLT）计数、活化部分凝血酶原时间（APTT）、超敏C反应蛋白（hs-CRP）浓度、药物不良反应发生情况。结果：治疗7 d后,两组与治疗前相比均有一定疗效,AA组总有效率显著高于LA组（P<0.05）。治疗后AA组NIHSS评分低于LA组（P<0.05）,Barthel指数明显高于LA组（P<0.01）。AA组治疗3个月后mRS评分明显低于LA组（P<0.01）。同时,治疗3个月时的mRS0-1评分占比相比,AA组优于LA组（P<0.05）。此外,AA组治疗后APTT长于LA组（P<0.01）,LA组PLT较AA组降低（P<0.01）。两组治...     

糖尿病对小剂量阿司匹林治疗的阿司匹林抵抗的影响及相关因素分析

目的 探讨糖尿病对小剂量阿司匹林治疗的阿司匹林抵抗(AR)的影响及相关因素分析.方法 选择328例病情稳定的心脑血管病患者或有心脑血管病危险因素者,按照是否合并2型糖尿病将其分为合并糖尿病组(101例)和非糖尿病组(227例).两组均给予阿司匹林100 mg/d口服,连服14 d后分别以花生四烯酸(AA)、二磷酸腺苷(ADP)作诱导剂检测两组血小板聚集率.以同时满足AA诱导的血小板聚集率≥20%及ADP诱导的血小板聚集率≥70%者为AR;仅满足一项者为阿司匹林半抵抗(ASR),均不满足者为阿司匹林敏感(AS).分析两组AR、ASR、AS发生情况及影响AR/ASR的危险因素.结果 (1)合并糖尿病组ASR、AR+ASR发生率分别为35.6%和42.6%,非糖尿病组分别为23.8%和27.8%,两组ASR及ASR+AR发生率间差异有统计学意义(P＜0.05).(2)合并糖尿病组和非糖尿病组AR+ASR患者除血糖水平[分别为(7.1±2.6)mmol/L和(4.8±0.6)mmol/L]间差异有统计学意义(P＜0.01)外,其他临床相关指标间差异均无统计学意义(P＞0.05).(3)合并糖尿病组AR+ASR患者女性(60.5%)、吸烟者比例(11.6%)及TG水平[(1.7±0.7)mmol/L]与合并糖尿病组AS患者[分别为41.4%、29.3%和(2.2±1.7)mmol/L]比较,差异均有统计学意义(P＜0.05).(4)女性是合并糖尿病患者发生AR/ASR的独立危险因素[β=-1.185,χ2=7.738,P=0.005,OR=0.306,95%CI为(0.133,0.705)].结论 服用小剂量阿司匹林的心脑血管疾病合并糖尿病患者ASR及AR+ASR发生率高于心脑血管疾病非糖尿病患者.性别可能是糖尿病患者发生AR/ASR的相关危险因素之一.     

噻氯匹啶对急性脑梗塞病人血小板聚集的抑制作用

目的观察国产噻氯匹啶对急性脑梗死病人血小板聚集的抑制作用;方法选择98例急性脑梗死病人,随机分为噻氯匹定组和阿司匹林组,噻氯匹啶组用噻氯匹啶,阿司匹林组用阿司匹林,数据用方差分析,差异性用t检验;结果2组用药后与用药前相比血小板聚集率均明显下降,(P<0．01),而2组间比较噻氯匹啶的作用大于阿司匹林(P<0．05);结论国产噻氯匹定对急性脑梗死病人的血小板聚集有肯定的抑制作用。     

Association of the Platelet Membrane Glycoprotein Ⅰa C807T Gene Polymorphism with Aspirin Resistance

To explore the correlation between the C807T polymorphism of platelet membrane gly- coprotein Ⅰa (GPⅠa) gene and aspirin resistance in Chinese people, 200 patients with high-risk of atherosclerosis took aspirin (100 mg/d) for 7 days. Platelet aggregation function was detected using adenosine diphosphate (ADP) and arachidonic acid (AA) before and after the administration of aspi- fin. Then the subjects were divided into three groups according to the results of platelet aggregation function: an aspirin resistant (AR) group, an aspirin semi-responder (ASR) group and an aspi- fin-sensitive (AS) group. Platelet GPⅠa gene 807CT polymorphism was examined by means of po- lymerase chain reaction-sequence specific primers (PCR-SSP). The results showed that T allelic fre- quency in AR group and ASR group were higher that of AS group (P<0.005), and the prevalence of genotypes (TT+TC) of these two groups was significantly higher than that in AS group (P<0.05). Platelet GPⅠa T allele was significantly associated with aspirin resistance as revealed by multiple logistic regression (OR=3.76, 95% CI: 2.87-9.58). The results suggest that inherited platelet GPⅠa variations may have an important impact on aspirin resistance and the presence of GPⅠa T allele may be a marker of genetic susceptibility to aspirin resistance.     

血浆钙离子浓度对血小板聚集的影响

目的 探讨血浆钙离子浓度对血小板聚集检验结果的影响.方法 采集健康志愿者静脉血标本(n=42),添加不同量的氯化钙,采用血浆比浊法进行血小板聚集率检测.结果 血浆Ca2+浓度在2.1-0.12mmol/l时,二磷酸腺苷(ADP)和花生四烯酸(AA)诱导的血小板聚集率分别为(75.9±10.4)％-(51.8±9.6)％和(83.7±13.9)％-(64.4±12.2)％,血小板聚集率随Ca2+浓度的降低而降低;血浆Ca2+浓度在2.1-33.66mmol/L时,ADP和AA诱导的血小板聚集率分别为(75.9±10.4)％-(94.7士4.8)％和(83.7士13.9)％-(93.2±5.5)％,随Ca2+浓度的增高而增高;Ca2+浓度为39.00mml/L时,血小板聚集率明显降低[ADP和AA诱导的血小板聚集率分别为(9.1±5.3)％和(11.1±4.5)％,均P＜0.01].结论 钙离子浓度波动对血小板聚集检验结果有明显影响.低于生理钙浓度(2.1mmol/L血小板聚集率随Ca2+浓度的降低而降低,高于生理钙浓度血小板聚集率随Ca2+浓度的增高而增高;血钙过高(≥39.0mmol/L)抑制血小板聚集.     

动脉粥样硬化高危人群中阿司匹林抵抗调查分析

目的调查社区动脉粥样硬化高危人群中阿司匹林抵抗(AR)或半抵抗(ASR)的发生率及其流行病学特征,并探讨其与危险因素的相关性。方法筛选200例动脉粥样硬化高危患者服用阿司匹林(100mg/d)至少7天以上,用二磷酸腺苷(ADP)和花生四烯酸(AA)作诱导剂测定其前后血小板聚集功能变化及血清血栓烷B2(TXB2)水平测定。结果200例动脉粥样硬化高危人群中AR发生率为4.5%,ASR者占20.7%。血清TXB2,AA、ADP诱导的血小板聚集率与健康对照组相比有显著统计学差异(P<0.01);血清TXB2与血小板聚集率有较好的相关性(r=0.871)。结论社区动脉粥样硬化高危人群服用阿司匹林后部分产生AR或ASR;AR或ASR人群发生冠心病事件的风险高于阿司匹林敏感(AS)人群;检测AA、ADP诱导的血小板聚集率,血清TXB2可作为动脉粥样硬化高危人群发生AR或ASR的评价指标。     

姜黄素、小檗碱及其配伍对db/db小鼠糖脂代谢的影响

[目的]观察姜黄素、小檗碱分别及其配伍对db/db小鼠糖脂代谢的影响,为中药配伍合理性提供实验依据。[方法]db/db小鼠口服给予姜黄素和小檗碱,28d后,观察分别及其配伍对小鼠体质量、脏器系数、血清基础血糖、糖耐量曲线、总胆固醇、甘油三酯、高密度脂蛋白胆固醇、低密度脂蛋白胆固醇的影响。[结果]各给药组均可显著降低db/db小鼠的肝脏系数(P0.05);姜黄素低剂量(19.5mg/kg)小檗碱高剂量(144mg/kg)配伍组和姜黄素高剂量(39mg/kg)小檗碱高剂量(144mg/kg)配伍组可显著降低db/db小鼠基础血糖(P0.05);姜黄素低剂量(19.5mg/kg)小檗碱高剂量(144mg/kg)配伍组和姜黄素高剂量(39mg/kg)小檗碱高剂量(144mg/kg)配伍组可显著调节改善db/db小鼠糖耐量曲线(P0.05);姜黄素低剂量(19.5mg/kg)组、姜黄素高剂量(39mg/kg)小檗碱低剂量(72mg/kg)配伍组和姜黄素低剂量(19.5mg/kg)小檗碱高剂量(144mg/kg)配伍组可明显降低db/db小鼠甘油三酯的水平(P0.05)。[结论]将小檗碱和姜黄素进行配伍组合,其改善db/db小鼠的糖脂代谢紊乱的作用优于单独给药组,且姜黄素低剂量(19.5mg/kg)小檗碱高剂量(144mg/kg)配伍组综合表现出更为明显的疗效。